Advanced Oncotherapy’s (AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement of a number of technical milestones, the successful integration of all the module types that constitute the LIGHT accelerator, and acceleration of the proton beam to an energy of 52MeV, sufficient to treat superficial tumours. With LIGHT, its breakthrough PBT technology, AVO is aiming to replicate the commercial success of MRI by opening new untapped markets with an innovative financing strategy.
13 May 2019
Commercialising a breakthrough technology
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Commercialising a breakthrough technology
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
13 May 2019 -
Author:
Martin Hall -
Pages:
24
Advanced Oncotherapy’s (AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement of a number of technical milestones, the successful integration of all the module types that constitute the LIGHT accelerator, and acceleration of the proton beam to an energy of 52MeV, sufficient to treat superficial tumours. With LIGHT, its breakthrough PBT technology, AVO is aiming to replicate the commercial success of MRI by opening new untapped markets with an innovative financing strategy.